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ApoptosisCell-penetrating peptides (CPPs) are a promising group of delivery vectors for various therapeutic agents but
their application is often hampered by poor stability in the presence of serum. Different strategies to improve
peptide stability have been exploited, one of them being “retro-inversion” (RI) of natural peptides. With this
approach the stability of CPPs has been increased, thereby making them more efﬁcient transporters. Several
RI-CPPs were here assessed and compared to the corresponding parent peptides in different cell-lines.
Surprisingly, treatment of cells with these peptides induced trypsin insensitivity and rapid severe toxicity in
contrast to L-peptides. This was measured as reduced metabolic activity and condensed cell nuclei, in parity
with the apoptosis inducing agent staurosporine. Furthermore, effects on mitochondrial network, focal
adhesions, actin cytoskeleton and caspase-3 activation were analyzed and adverse effects were evident at
20 μM peptide concentration within 4 h while parent L-peptides had negligible effects. To our knowledge this
is the ﬁrst time RI peptides are reported to cause cellular toxicity, displayed by decreased metabolic activity,
morphological changes and induction of apoptosis. Considering the wide range of research areas that involves
the use of RI-peptides, this ﬁnding is of major importance and needs to be taken under consideration in
applications of RI-peptides.o inverso; PNA, peptide nucleic
; FA, focal adhesion
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.
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Cell-penetrating peptides (CPPs) are relatively short, cationic and/
or amphipathic peptides that have successfully been exploited to
convey a wide range of cargos into different cell-lines in vitro, as well
as in vivo. The major advantages associated with this class of delivery
vectors, apart from their high delivery efﬁcacy, is that they generally
display low toxicity and that there appear to be no size restraints in
terms of cargo compounds that can be transported into cells using
these peptides [1]. One shortcoming, however, that has been realized
in the last few years, is the frequent accumulation of CPPs in the
endosomal compartments, which greatly reduces the bioavailability
of the cargo molecules. Several different strategies have successfully
been explored to overcome this problem, either by introducing
chemical modiﬁcations in CPPs or by conjugating fusogenic peptides
to CPPs [2,3]. Another major issue that needs to be addressed is the
rapid degradation of CPPs in the presence of serum. Almost allnaturally occurring polypeptides are composed of L-amino acids and,
consequently, the cellular proteolytic machinery does not recognize
D-amino acids. Thus, substituting L- with D-amino acids in a peptide
sequence increases its stability. This approach has proven successful
for several CPPs, e.g. polyarginine, pVEC, and penetratin [4,36,5].
However, this conversion yields peptides which are enantiomers and,
thus, the stereochemistry is not the same. Although making
polyarginine and pVEC more stable and thereby more efﬁcient
transporters, the stereochemistry might be important for other
CPPs. Furthermore, this modiﬁcation is not suitable when the
topology of the peptide is essential for activity.
In the early 1980s, Chorev and Goodman carried out extensive
research on the chemistry of peptide backbonemodiﬁcations [6]. They
hypothesized that exchanging a natural peptide sequence with all-D
amino acids (inverso) and reversing the order (retro) would yield a
peptide with the same stereochemistry as the parent peptide. These
peptidomimetics were named retro inverso (RI) peptides, where the
side groups are oriented in the same way, but the amine and carbonyl
of the amide peptide bond are reversed. In an extensive review from
2005, Chorev [7] presents a number of successful implementations of
the RI concept. However, RI modiﬁcation of natural peptides has a
history of mixed success and several groups have reported that their
RI-peptides lost the biological activity of the parent L-peptide [8,9].
Also CPPs have been subjected to this modiﬁcation, with the aim of
producing transporters with increased stability. To our knowledge the
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RI forms are the frequently used Tat [10] and penetratin peptides [11].
The aim of our study was to increase the stability of a CPP (M918)
designed in our lab, thereby making it a more potent transporter [12].
Another CPP (p14Arf), previously reported by our group to have
apoptogenic effects was also subjected to the RI modiﬁcation in order
to enhance its efﬁcacy [13]. The two most commonly used CPPs Tat
and penetratin were studied in RI mode for comparison. The results
indicate that cytotoxicity arises with RI-peptides above a certain
length. Also the high number of hydrophobic amino acids in the
peptide sequence might have a role in the induction of toxicity.
2. Materials and methods
2.1. Peptide synthesis
Peptides with either L- or D-amino acids, PNA and peptide-PNA
conjugates were synthesized with t-Boc chemistry as described in
[13].
2.2. Cell culture
MCF-7 and MDA MB 231 (human breast cancer cell lines) cells
(ATCC) were cultured in RPMI-1640 medium supplemented with FBS
(10%), penicillin (100 U ml−1), streptomycin (100 μg ml−1), sodium
pyruvate (1 mM), and non-essential amino acids (1%). HeLa pLuc 705
cells, kindly provided by R. Kole, were cultured in DMEM with
glutamax, using the same supplements as above. HeLa cells were
cultured in IMDM medium supplemented with FBS (10%), penicillin
(100 Uml−1) and streptomycin (100 μgml−1). All cells were grown at
37 °C and 5% CO2 and all cell culture material were purchased from
Invitrogen.
2.3. Cell proliferation assay
Cell proliferation was studied with the Roche Wst-1 proliferation
assay according to the manufacturer's instructions (Roche Diagnostics
Scandinavia AB, Sweden). Brieﬂy, cells were seeded in 96 well plates
2 days prior the experiment to reach 80% conﬂuency. Peptides were
added at different concentrations in RPMI or IMDM medium (100 μl)
followed by incubation for 4 h. The peptide solution was removed,
fresh medium added and the incubation was continued for another
20 h. Wst-1 substrate (10 μl) (Roche) was added to every well and
after 1–4 h absorbance was measured (450 nm) using Digiscan
absorbance reader (Labvision via AH Diagnostics AB, Sweden). The
percentage of viable cells was determined using GraphPad Prism
software 4.0 (GraphPad Software, CA).
2.4. Membrane integrity assay
Membrane integrity was assessed using the Promega CytoTox ONE
assay (Promega, Sweden). In brief, cells were seeded in 96-well plates
two days prior the experiment to reach 80% conﬂuency. Peptideswere
added at different concentrations in Hepes Krebs Ringer (HKR) (100
μl) and after 30 min incubation the exposure solution was transferred
to a 96-well black plate, followed by addition of the CytoTox-ONE™
reagent. The plate was incubated for 10 min at RT and then
ﬂuorescence was measured (560/590 nm) with SPECTRAmax®
GEMINI XS spectroﬂuorometric plate reader (Molecular Devices,
USA). The results are presented as percentage of the maximum LDH
release (100%) from 0.18% Triton X-100 treated cells.
2.5. Splice correction
60000 HeLa pLuc 705 cells/well were seeded in 24-well plates.
After 24 h, medium was removed and cells were overlaid withCPP-PNA conjugates at different concentrations in 500 μl optiMEM®
reduced serum media (Invitrogen). Cells were incubated for 4 h
whereafter 1 ml of full growth medium was added to each well. After
an additional 20 h, medium was removed and cells were washed
twice with HKR and subsequently lysed using 100 μl of 0.1% Triton
X-100 in HKR. After 30 min incubation on ice, 20 μl cell lysates were
transferred to white 96-well plates. Luciferase activity in cell lysates
was measured on a Flexstation II (Molecular Devices, USA) using the
Promega luciferase assay system according to manufacturers protocol
(Promega) and normalized to protein content.
2.6. Fluorescence microscopy on ﬁxed cells
35000 HeLa or MDA MB 231 cells/well were seeded onto glass
coverslips (Ø 12 mm, Marienfeld Superior, Germany) in 24-well
plates 2 days before experiment. On the day of experiment, cells were
washed, incubated with 10 or 20 μM peptides for 4 h in serum free
IMDM or RPMI medium at 37 °C (for negative control, cells were
incubated 4 h in medium without peptides), washed again and ﬁxed
with 4% paraformaldehyde (PFA) in PBS on ice for 30 min. Permea-
bilization of cells was performed with 0.1% Triton X-100 in PBS on ice
for 5 min, cells were then blocked with 10% non-fat dry milk (NFDM)
in PBS for 30 min and incubated with either 8.5 μg ml−1 rabbit
polyclonal antibody to zyxin (for staining of focal adhesions)
(ab11518, Abcam, UK) in 1% NFDM in PBS for 1.5 h and 10 μg ml−1
goat-anti-rabbit-Alexa-594 (Molecular Probes, OR) in 1% NFDM in PBS
for 1 h or with 0.4 U ml−1 phalloidin-Alexa-488 (Molecular Probes,
OR) in 1% NFDM in PBS. As positive control for actin polymerization,
cellular actin ﬁbers were induced with 5 μM lysophosphatidic acid
(LPA) for 15 min, following the above described protocol for cell
ﬁxation and actin visualization. Cells were mounted with either 30%
glycerol in PBS or Fluoromount (Sigma, MO) and visualized by
Olympus FV1000 confocal microscopy (zyxin/focal adhesions) or
Olympus BX61 microscope equipped with a CCD camera DP70
(phalloidin/actin). For visualization of caspase-3, cells were incubated
with 20 μM penetratin, RI-penetratin, Arf1-14 or RI-Arf1-14, or 50 μM
RI-penetratin or RI-short penetratin as described above, afterwards
ﬁxed and stained for caspase-3 according to the manufacturer's
protocol (R&D Systems, Inc., MN). Brieﬂy, treated cells were ﬁxed
with freshlymade 4% PFA in PBS for 30 min on ice, incubatedwith 1 μg
ml−1 rabbit polyclonal caspase-3 antibody in PBS containing 1% BSA,
1% goat serum and 0.3% Triton X-100 for 30 min in a humidiﬁed
chamber. Cells were then incubated with goat anti-rabbit-Alexa-594
secondary antibody (Molecular Probes, OR) (1:250 dilution in 1% BSA
in PBS) for 30 min. Additionally, DAPI staining (0.5 μg ml−1) was
performed. Cells were mounted to 30% glycerol in PBS and imaged by
Olympus FV1000 confocal microscope.
2.7. Fluorescence microscopy on live cells
8000 HeLa or MDA MB 231 cells/well were seeded onto
8-chambered cover glasses (Nalge Nunc International, NY) 2 days
before experiment. Cells were incubated with 10 or 20 μM long RI-
and L-peptides, or 50 μM RI-short penetratin for either 3 h (MDA MB
231), visualized immediately after adding the peptides for 0–45 min
(timelapse) or pulsed for 4 h and chased for additional 20 h (HeLa) at
37 °C. 45 min prior to visualization, 10 nM MitoTracker (M7512,
Molecular Probes, OR) was added. Cells were imaged using an
Olympus FV1000 confocal microscope and images were analyzed
with Olympus FV10 ASW software version 1.6.
2.8. Hoechst staining
Cells were seeded on cover slips in 24-well plates two days before
the experiment, to reach a conﬂuency of 70–80% on the day of the
experiment. Peptides were added at different concentrations in RPMI
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fresh medium added and incubation continued for another 20 h. The
coverslips were washed, ﬁxed with 4% PFA, stained with Hoechst
33342 for 5 min at RT, washed, mounted on glass slides, and then
analyzed by ﬂuorescence microscopy (Leica DMIRE2 ﬂuorescence
microscope). Quantiﬁcation of the cell images (nN400 for each
treatment) was done by counting the number of condensed and
normal nuclei, then calculating the percentage of condensed nuclei
and normalizing it against staurosporine treated cells.
3. Results
3.1. Cellular translocation of ﬂuoresceinyl-labeled RI-CPPs
Five RI-peptides and their normal counterparts composed of
L-amino acids were synthesized and evaluated in this study (Table 1).
To establish that the peptides retained their cell-penetrating ability
after RI-isomerization, they were all labeled N-terminally with
ﬂuorescein and cellular uptake was conﬁrmed with confocal micros-
copy. Within 30 min at 5 μM concentration, all peptides displayed a
vesicular-like uptake pattern (data not shown).
3.2. Retro inversion of CPP does not confer increased cellular internalization
M918 is an efﬁcient CPP recently discovered by EL Andaloussi et al.
[12]. This peptide is capable of delivering various cargos including
plasmids, proteins and oligonucleotides into a wide range of cell-lines.
With the aim of making this CPP more stable, and thereby possibly
more efﬁcient, we synthesized its retro-inverso analogue. The splice
correction assay has become a powerful method in evaluation of the
delivery properties of CPPs since it generates a biological positive
read-out (for a detailed description of the method, see [14,15]). This
assay makes use of HeLa cells that are stably transfected with a
luciferase reporter gene that is interrupted by a thalassemic intron
carrying an aberrant splice site [15]. Under normal conditions, these
HeLa pLuc 705 cells will produce luciferase transcripts carrying parts
of the intron and concomitantly non-functional luciferase protein is
produced. However, if a steric block splice-correcting oligonucleotide
that binds complementary to the mutated position is introduced to
the nucleus of cells, splicing will be re-directed and functional
luciferase produced. Thus, by covalently conjugating RI-M918 to
splice correcting antisense peptide nucleic acid (PNA) oligomer
(Table 1) the delivery properties could be assessed by measuring
the increase in luminescence. Surprisingly, RI-M918-PNA was not
signiﬁcantly better than M918-PNA at inducing splice correction at 2
and 5 μM, and at 10 μM correctionwas abolishedwhen using RI-M918
whereas the parent M918-PNA promoted a further increase in spliceTable 1
Names and sequences of the peptides and PNA used in the study.
Name Sequence
Arf 1-14 MVRRFLVTLRIRRA-amide
RI-Arf 1-14 arrirltvlfrrvm-amide
RI-Arf1-14 inv arrirlrrﬂvtvm-amide
M918 MVTVLFRRLRIRRASGPPRVRV-amide
RI-M918 vrvrppgsarrirlrrﬂvtvm-amide
Penetratin RQIKIWFQNRRMKWKK-amide
RI-penetratin kkwkmrrnqfwikiqr-amide
Tat YGRKKRRQRRR-amide
RI-Tat rrrqrrkkrgy-amide
RI-short penetratin nqfwikiqr-amide
M705 PNA CysKKCCTCTTACCTCAGTTACAKK-amide
Peptides are ﬂuoresceinyl-labeled on the N-terminus. Lower case letters indicate D-
amino acids. Bold letters represent nucleobases. For the formation of conjugates, M918
and RI-M918 were synthesized with N-terminal Cys(Npys). Conjugates are illustrated
as follows: CPPCys-S-S-CysPNA and abbreviated, e.g. M918-PNA.correction (Fig. 1). The drop in luminescence at 10 μM RI-M918
suggests that the cells are not viable and unable to produce luciferase.
3.3. RI-CPPs reduce the viability of cells
All peptides (Table 1) were assessed using the Wst-1 assay to
determine their impact on cell viability. In our previous publication on
the use of the p14Arf peptide [13] (from now on called Arf1-14), two
different breast cancer cell-lines were used; MDA MB 231 and MCF-7.
In order to compare the effects of RI-Arf1-14 and its parent peptide,
the same cells were used and, in addition, the effect on HeLa cells was
investigated, since this is one of the most commonly used cell-line.
Staurosporine, an apoptosis-inducing agent, was included as control.
None of the control peptides composed of L-amino acids reduced the
viability of cells, and every RI-peptide was normalized against its
L-peptide counterpart. In keeping with the results from the splice
correction assay, RI-M918 reduced the cellular viability by 30% in
HeLa cells at 10 μM (Supplementary Fig. S1b), and the effect was even
more pronounced in the other cell-lines (50-70% reduction) (Fig. 2
and Supplementary Fig. S1a). RI-Tat and RI-short penetratin were not
toxic in the tested concentration range. However, full length RI-
penetratin (RI-penetratin) had a dramatic effect on cellular viability.
At 10 μM, it reduced the viability by 75% in MDAMB 231 cells (Fig. 2).
This is remarkable since staurosporine only reduced viability by 50%.
The effect of RI-Arf1-14 was similar in both MDA MB 231 and MCF-7
cells, with 40–50% reduced viability at 10 μM concentration and
80–90% reduced viability at 20 μM (Fig. 2 and Supplementary Fig.
S1a). HeLa cells are more robust and although signiﬁcant reduction in
viability was observed, none of the RI-peptides reduced the viability
by more than 50% (Supplementary Fig. S1b).
To rule out that the observed toxic effects were due to extensive
membrane damage after peptide treatment, leakage of lactate
dehydrogenase (LDH) was measured. None of the peptides caused
leakage above 8% in any of the tested cell-lines up to 20 μM
concentration (Supplementary Fig. S2a–c).
3.4. RI-CPPs induce trypsin insensitivity of treated cells
The amount of apoptotic cells was initially assessed by the Annexin
V assay. Surprisingly, cells treated with RI-CPPs did not detach from
the plastic neither with enzymatic trypsin treatment nor with EDTA.
The possibility of RI-peptides inhibiting the trypsin activity was
assessed and no interference with its enzymatic activity was observed
for any of the RI-peptides (data not shown). Therefore, to visualize the
morphological changes in cells after RI-CPP treatment, MDA MB 231
and HeLa cells were incubated with 20 μM penetratin, RI-penetratin,Fig. 1. Retro inversion of the CPP does not confer increased cellular internalization.
Splice correction was measured 24 h after treatment with CPP-PNA conjugates at the
indicated concentrations. Light emission (RLU) is normalized to the protein content in
each well and data presented as RLU/mg. Depicted are mean and standard error of the
mean (SEM) of triplicate results that are representative of multiple experiments.
Fig. 2. RI-CPPs reduce the viability of cells. Cell viability of MDA MB 231 cells was
determined by measuring their metabolic activity with the Wst-1 assay. Cells were
treated with peptides at indicated concentrations for 4 h. The peptide solution was then
removed, fresh medium added, and cells were incubated for another 20 h.
Staurosporine (0.5 µM) was included as positive control. The effect of RI-peptides on
viability was normalized against the effect of their L-peptide counterpart. Mean and
standard error of the mean (SEM) of multiple experiments are depicted.
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trypsin treatment was carried out to observe cell rounding effects
using confocal microscopy where time-lapse images were taken after
every 15 s (Supplementary Fig. S3a–h and Supplementary movies
M1).
M918, penetratin and Arf1-14 did not alter the phenotypic
appearance of the cells and during trypsin treatment, all the cells
turned spherical within 2–5 min (Supplementary Fig. S3a, c, e and g,
Supplementary movie M1 a, c, e and g, and data not shown).
Additionally, propidium iodide (PI), which is impermeable to cells
with intact membranes, did not stain any of the visualized cells.
RI-M918 (data not shown), RI-Arf1-14 and RI-penetratin, on the other
hand, generated a remarkable change in the morphology of MDA MB
231 cells with a strongly granulated cytoplasm, a blebbing plasma
membrane and a risen/mispositioned nucleus (Supplementary Fig.
S3b and d. Supplementary movie M1, b and d). When applying
trypsin, we observed no movement or rounding of cells even after
15 min. RI-CPPs clearly exerted a cytotoxic effect on the cells detected
as severe morphological alterations and strong intracellular PI signal.
3.5. RI-CPPs prohibit formation of focal adhesions and induce
disassembly of the actin cytoskeleton
Since trypsin had no effect on cells treated with RI-CPPs and that
cells were ﬁrmly attached to the plastic even after longer enzymatic
treatment, we investigated the condition of focal adhesions (FAs) in
cells possessing the risen nucleus phenotype. For that, HeLa cells were
incubated with 10 (Supplementary Fig. S4) or 20 μM (Fig. 3)Fig. 3. RI-CPPs prohibit the formation of focal adhesions. Focal adhesions in HeLa cells were vi
µM Arf1-14, RI-Arf1-14, penetratin or RI-penetratin for 4 h. Control cells were incubated inpenetratin, RI-penetratin, Arf1-14 or RI-Arf1-14 for 4 h at 37 °C and
focal adhesion protein zyxin was visualized by immunoﬂuorescence
and microscopic analysis.
FAs in penetratin- and Arf1-14-treated cells were similar to control
cells, where zyxin was located in short and relatively thick bundles
(Fig. 3 and supplemental Fig. S4). RI-penetratin, induced the
formation of longer and thinner adhesive structures, especially
when lower concentration (10 μM) was used.
RI-Arf1-14-treatment (20 μM) led to the disappearance of all FAs
in cells possessing the risen nucleus phenotype (Fig. 3). In the few
cells (about 5%) still forming observable FAs after 10 μM RI-Arf1-14
treatment, the FAs were similar to those found in RI-penetratin
treated cells with an extended and thinner appearance (Supplemen-
tary Fig. S4).
The actin ﬁlaments, as one of the cellular cytoskeletal components
responsible for cell stretching, adhesion and intracellular mechanical
tension, terminate with focal adhesions at the cell membrane [16].
Since drastic alterations in adhesive structures were observed in RI-
CPP-treated cells, we next analyzed the intactness of the actin
cytoskeleton in MDA MB 231 and HeLa cells after treatment with
20 μM peptides for 4 h by visualizing the polymerized actin with the
phalloidin-staining.
In MDA MB 231 cells, both RI-penetratin and RI-Arf1-14
dissociated the central actin ﬁlaments, leading to a diffuse
unorganized localization of actin (Fig. 4). The cortical actin ﬁbers
were, however, present in most of the RI-penetratin-treated cells. In
contrast, when using RI-Arf1-14, the cortical actin bundles were
missing in approximately 80–90% of cells. Additionally, the induc-
tion of ﬁlopodia-like structures was observed in RI-peptide-treated
cells, especially with RI-Arf1-14, where the membrane area was
undulating more as a result of the loss of stabilizing cortical actin.
The L-counterpart peptides did not affect the cells and the actin
skeleton was similar to control cells.
In HeLa cells, RI-penetratin-treatment destroyed most of the
central actin ﬁlaments and led to the formation of large ﬂat areas lined
with numerous ﬁlopodia-like structures (Supplementary Fig. S5). RI-
Arf1-14 affected both types of actin ﬁlaments, disassembling the
cortical along with the central actin cables. Corroborating the results
in MDA MB 231 cells, HeLa cells treated with penetratin and Arf1-14
did not appear different from the control cells.
3.6. RI-CPPs disrupt the mitochondrial network and induce apoptosis
In light of the extreme morphological and cytotoxic effects of the
studied RI-peptides, we examined the integrity of the mitochondrial
network inMDAMB 231 and HeLa cells usingMitoTracker as amarker
for active mitochondria. During early apoptotic events the inner
mitochondrial transmembrane potential is disrupted [17], leading to a
decreased signal from the MitoTracker probe.
The L-peptides did not affect themitochondrial potential neither in
MDA MB 231 (Fig. 5) nor in HeLa cells (Supplementary Fig. S6). RI-sualized with anti-zyxin antibody after peptide treatment. Cells were incubated with 20
IMDM medium without peptides. Bar 10 µm.
Fig. 4. RI-CPPs induce disassembly of the actin cytoskeleton. MDAMB 231 cells were treated with 20 µM penetratin, RI-penetratin, Arf1-14 or RI-Arf1-14 for 4 h. Cellular actin ﬁbers
were induced with 5 µM lysophosphatidic acid (LPA) for 15 min as positive control for actin polymerization (upper right panel). Untreated cells incubated in RPMI medium are
shown in the lower right panel (no peptide). The actin cytoskeleton was visualized with phalloidin-Alexa-488. Image has been color-inverted for better visualization of actin
ﬁlaments. Bar 10 µm.
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mitochondrial network already after 3 h, especially in MDA MB 231
cells (Fig. 5). RI-penetratin-treatment caused disruption of the
mitochondrial network in about 50% and RI-Arf1-14 in more than
95% of cells. In HeLa cells, RI-Arf1-14-treatment completely abolished
the mitochondrial network. RI-penetratin had a much milder impact
on HeLa cells and the mitochondrial network was still apparent
(supplemental Fig. S6). The short penetratin analogue RI-short
penetratin did not cause any visible discrepancies in the mitochon-
drial network compared to the untreated cells even at higher
concentrations (50 μM) (Fig. 5).
We also analyzed the effect of RI-Arf1-14 on the mitochondria in a
time dependent manner and detected the ﬁrst variations in
mitochondrial signals already after 15–20 min (supplemental movie
M2). The gaps in the network grew larger until completely
disappearing after 45 min–1 h incubation. Along with the loss of
mitochondrial signal, the cells underwent the morphological changes
described above.
The observed nuclear changes and the possible involvement of
apoptosis were further investigated by Hoechst staining of condensed
nuclei. Cells treated with peptides, or staurosporine, were stainedFig. 5. Longer RI-peptides disrupt the mitochondrial network. The mitochondrial network
confocal microscopy. Cells were incubated with 20 µM penetratin, RI-penetratin, Arf1-14 owith Hoechst nuclear dye and analyzed by ﬂuorescence microscopy.
The L-peptides (M918, Arf1-14, penetratin and Tat) did not induce
changes in nuclear morphology, while the RI-peptides (RI-M918, RI-
Arf1-14 and RI-penetratin) induced chromatin condensation compa-
rable with, or higher than, staurosporine. Cells treated with L-peptides
or RI-Tat and RI-short penetratin displayed condensed nuclei in the
same range as the untreated cells (Fig. 6).
3.7. RI-CPPs activate caspase-3
During apoptosis, several cellular caspases, e.g. caspase-3, are
crucial mediators for inducing the programmed cell death [18]. Since
the aforementioned alterations in cell viability, morphology, attach-
ment andmitochondria refer to the induction of apoptosis, we studied
the caspase-3 activation inMDAMB 231 and HeLa cells. The cells were
treated with 20 μM penetratin, RI-penetratin, Arf1-14 or RI-Arf1-14,
or 50 μM RI-penetratin and RI-short penetratin for 4 h. We observed a
signiﬁcant induction of caspase-3 activation in response to RI-Arf1-
14-treatment in both cell lines (MDA MB 231 (Fig. 7) and HeLa
(Supplementary Fig. S7)). Surprisingly, RI-penetratin did not induce
activation of caspase-3 at 20 μM concentration, although slightlyin MDA MB 231 cells was labeled with MitoTracker 45 min prior to visualization with
r RI-Arf1-14, or with 50 µM RI-short penetratin (RI-short pen) for 3 h. Bar 10 µm.
Fig. 6. RI-CPPs induce nuclear condensation. MCF-7 cells were incubated with peptides
at 10 or 20 µM concentration for 4 h. The peptide solution was then removed, fresh
medium added, and the cells were incubated for another 20 h. Cell nuclei were stained
with Hoechst nuclear dye and analyzed with ﬂuorescence microscopy. Quantiﬁcation
was done by counting the number of normal nuclei and nuclei with condensed
chromatin for each concentration (at least 400 cells). Results are presented as percent
of condensed nuclei normalized to 0.5 µM staurosporine (sts) treated cells.
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cells as compared to control or L-peptide-treated cells. However,
increasing the concentration of RI-penetratin to 50 μM resulted in
similar activation of caspase-3 as in RI-Arf1-14-treated cells. Similar
effect was seen with RI-M918, where a higher concentration (50 μM)
of the peptide was needed to induce caspase-3 activation (data not
shown). On the other hand, neither RI-short penetratin (Fig. 7) nor RI-
Tat (data not shown) affected caspase-3 activation even at higher
concentrations.
4. Discussion
The stability of the potent transport vectors called cell-penetrating
peptides (CPPs) in the presence of serum or blood plasma has
emerged as one of the limiting steps in their successful application in
vivo [19]. To increase the peptide's resistance to premature degrada-
tion or proteolysis, several methods have been used, including
D-isomerization and retro-inversion (RI) techniques. With the aim
of improving the stability of a novel CPP called M918 displaying
improved transporting abilities in different cell-lines [12], we
synthesized its RI counterpart. When assessing the transport
efﬁciency of M918 and its RI-isoform, we unpredictably found that
cells treated with RI-M918-PNA displayed drastic morphological
changes, indicative of cytotoxicity.
Another effective CPP p14Arf, which has been shown to induce
apoptosis, [13] was subjected to the RI isomerization. However, since
it has been reported that the N-terminal 14 amino acids of p14Arf are
sufﬁcient for peptide activity [20], we made p14Arf 1-14 in RI mode.
As a control peptide, p14Arf1-14 with L-amino acids was synthesized.
The initial results were promising since the cell-penetrating capability
was retained and Wst-1 data showed that RI-Arf1-14 reduced the
viability of MDA MB 231 and MCF-7 cells by 50% at 10 μM
concentration (Fig. 2 and Supplementary Fig. S1a), without causing
leakage of LDH (Supplementary Fig. S2). However, to ascertain that
the reduced viability was not due to unspeciﬁc toxicity, but indeed
due to the interaction of RI-Arf1-14 peptide with its target protein
[13], a control peptide was synthesized, where the ﬁve amino acids
crucial for target interaction were inverted, producing a peptide with
no effect on cell viability. Unexpectedly, this peptide caused an
analogous reduction in cell viability as RI-Arf1-14 (data not shown),
suggesting that the reduced proliferation was not due to RI-Arf1-14
per se, but more likely as a result of the RI modiﬁcation of the peptide.
In order to verify our ﬁndings, two widely used CPPs–Tat andpenetratin–were synthesized in the RI-mode and analyzed for
cytotoxicity. RI-penetratin was found to be as cytotoxic as RI-Arf1-
14 and RI-M918, as determined with the Wst-1 assay (Fig. 2), while
RI-Tat did not affect the cells at all. In addition, we also found that cells
treated with RI-Arf1-14, RI-M918 and RI-penetratin, could not be
detached from the cell culture plates, neither with trypsin nor with
EDTA. This observation, together with the results from splice
correction and Wst-1 assays, were the ﬁrst indications that RI-
peptides might cause adverse cellular effects and it prompted us to
investigate this phenomenon further.
Treatment of both MDA MB 231 and HeLa cells with RI-penetratin
and RI-Arf1-14 induced extensive alterations in cell morphology. As
depicted in Fig. 3 and 4, the mechanism(s) behind these alterations
may lie in the structural changes of the actin cytoskeleton and
concomitantly the focal adhesions due to treatment with the RI-
peptides. Since some CPPs have been demonstrated to directly
interact with the monomeric actin [21], they could, as a result, also
interfere with the polymerization or rearrangement processes causing
the above mentioned effects. Moreover, due to the increased stability
of the RI-peptides, their effects inside the cells could be ampliﬁed by
several fold because of their lack of removal by the cell's proteolytic
machinery. Additionally, the actin cytoskeleton and its remodeling
plays a crucial role in many cellular processes, i.e. cell spreading,
adhesion, contraction, etc. [22] and, therefore, its disruption or
depolymerization may lead to inhibition of cellular events resulting
in abnormal functioning of the cell. For example, it has been shown
that the actin cytoskeleton is involved in the cortical retraction of
mitotic cells and in case of its disruption by inhibition of upstream
effectors (i.e. RhoA and Rho-kinase/ROCK), the cells undergoing
mitosis do not turn spherical [23]. Similar outcome was observed in
our trypsin-treatment experiments, where cells without the presence
of actin ﬁlaments did not obtain a globular form. Also, the risen
nucleus of RI-peptide-treated cells is possibly caused by the
disassembly of the actin skeleton since actin ﬁlaments are essential
for nuclear positioning and anchorage [24]. Furthermore, it has been
shown that actin disruption may evoke apoptosis [25], afﬁrming the
damage that some of the RI-peptides cause the cells.
Adverse toxic effects were observed for all the RI-peptides, except
for RI-Tat. Since RI-Tat is only 11 amino acids long, we hypothesized
that this could be one of the reasons for the observed difference in
toxicity of the RI-peptides. We therefore synthesized a truncated
version of RI-penetratin with only the ﬁrst 9 amino acids, named RI-
short penetratin. This peptide was also nontoxic to the cells,
suggesting that RI-peptides above a certain length cause these
adverse effects. The importance of the peptide length on the
cytotoxicity has been demonstrated before for e. g. polyarginine
[26]. The length of the peptide may determine, for example, the depth
of membrane insertion, since it has been demonstrated with
Transportan (TP) [27], that the longer peptides are capable of
spanning the whole lipid bilayer, whilst shorter peptides can
submerge only to the outer membrane leaﬂet. Additionally, the
shortening of MAP peptide by four amino acid residues either N- or C-
terminally (corresponding to the removal of one of theα-helix turns),
eliminated its toxic effects [28]. The results onMAP indicate that there
may be a correlation between helicity (a membrane interacting
secondary structure) and cytotoxicity. We therefore hypothesize
further that the ability to form secondary helical structure is
important for efﬁcient internalization but might also cause toxicity.
Grounds for such hypothesis comes from the notion that all the toxic
peptides used in this study–RI-Arf1-14, RI-penetratin, and RI-M918–
contain amino acids that are frequently found within helices, e. g.
alifatic amino acids, whereas RI-Tat is mostly composed of cationic
residues that are less likely to form a helix. Also, both RI-Tat and RI-
short penetratin are likely too short to form a secondary structure.
Furthermore, as demonstrated by EL Andaloussi et al [29], the
quantitative uptake of Tat is about 50 times lower than penetratin
Fig. 7. RI-Arf1-14 (20 µM) and RI-penetratin (50 µM) induce activation of caspase-3. Caspase-3 antibody with the secondary Alexa594-conjugated antibody was used to visualize
activation of caspase-3 after peptide treatment. MDA MB 231 cells were incubated with 20 µM Arf1-14, RI-Arf1-14, penetratin, RI-penetratin or 50 µM RI-penetratin or 9-mer RI-
short penetratin (here RI-short pen) for 4 h. Lower panels show DAPI stained cells. Control cells were incubated in RPMI medium without the peptides (no peptide). Bar 10 µm.
1550 T. Holm et al. / Biochimica et Biophysica Acta 1808 (2011) 1544–1551at 5 μM, corroborating the result of many different groups that Tat
peptide per se is not very potent in entering cells [30–32]. Therefore,
the difference in toxicity displayed by the short versus the longer RI-
peptides may additionally be due to higher intracellular levels of the
latter.
Put together, the combination of peptide length, a high positive
charge and existence of hydrophobic amino acids allowing the
formation of regular secondary structures make the peptides more
prone to ﬁrst interact with the plasma membrane components, and
second, associate better with the membrane lipids, leading to a
stronger membrane perturbation ability. Since RI-Tat is devoid of
hydrophobic amino acids that could potentially affect the membrane
stability, it is not considered a membrane active peptide (at least in
the concentration range used in this study). We have observed an
increased membrane interaction with all the longer more hydropho-
bic RI-peptides by the induction of intracellular PI staining (data not
shown). The fact that even though strong PI staining was recorded but
LDH leakage was not observed during treatment with the toxic RI-
CPPs indicates that the RI-peptides do not damage the membrane tothe extent that large molecules could pass through the damaged
regions. Instead, local disturbances of the lipid bilayer may be induced
leading to the entrance of the small PI molecules. Taken together,
because of both the length and the high number of hydrophobic
amino acid residues in their sequence, the used (longer and
hydrophobic) RI-CPPs may also interact and destabilize the intracel-
lular mitochondrial membranes, causing the observed loss in the
mitochondrial potential (Fig. 5, Supplementary Fig. S6 andmovieM2).
However, due to the lack of further evidence, we cannot rule out the
possibility that RI-CPPs act indirectly upon the mitochondrial
potential and activity. Nevertheless, the maintenance of the trans-
membrane potential is required for most mitochondrial functions and
under apoptotic conditions the gradual loss of the mitochondrial
membrane potential causes a decline in the generation of ATP and
ultimately leads to cell death [33]. Therefore, the RI-peptide-
treatment negatively affecting the mitochondrial network gives
further evidence for cytotoxic effects of the RI-modiﬁcation and may
possibly refer to a process of apoptosis. Our results illustrate that
changes in the mitochondrial network are actually the ﬁrst signs of
1551T. Holm et al. / Biochimica et Biophysica Acta 1808 (2011) 1544–1551cytotoxic activity displayed by the longer hydrophobic RI-peptides
(observed already after 15 min, Supplementarymovie M2), indicating
that this could be the initiator of the successive events.
To deﬁne if the cells underwent apoptotic events after RI-peptide
treatment, their nuclear morphology was characterized by Hoechst
staining. All three RI-peptides which reduced the cell viability, RI-
Arf1-14, RI-M918 and RI-penetratin, affected the cell nuclei in the
same range as staurosporine (Fig. 6). This method is not speciﬁc
enough to be used as a single approach to determine the involvement
of apoptosis, but it provides general information if and to what extent
the nuclei are affected. A more speciﬁc approach is to measure the
activation of caspases, such as caspase-3. 20 μMRI-penetratin induced
a weak, but measurable, activation of caspase-3 in MDA MB 231 cells
(Fig. 7). The same concentration of RI-Arf1-14, on the other hand,
clearly activated caspase-3 in both MDAMB 231 and HeLa cells (Fig. 7
and Supplementary Fig. S7). Elevating the RI-penetratin concentra-
tion, however, induced the same extent of caspase-3 activation as
observed in RI-Arf1-14-treated cells (Fig. 7). Thus, the mechanism
behind the toxic effects of RI-penetratin and RI-Arf1-14 differs or,
alternatively, RI-penetratin is a less potent apoptosis inducing
peptide. RI-Arf1-14 induced the same morphological changes as RI-
penetratin, but the effect was faster and more severe with diminished
focal adhesions and mitochondrial network. The diminished mito-
chondrial potential and the strong activation of caspase-3 after RI-
Arf1-14 treatment in both MDA MB 231 and HeLa cells indicate that
this peptide is most likely inducing its effect through apoptosis.
However, caspase-3 activation is not an absolute requisite for deﬁnite
induction of apoptosis and several caspase-independent cell death
processes have been described [33–35]. Therefore, although RI-
penetratin at lower concentrations did not activate caspase-3, it
could still induce apoptosis through disruption of the mitochondrial
potential and the actin cytoskeleton.
In summary, we hypothesize that the loss of mitochondrial
transmembrane potential by RI-peptides could trigger the cascade of
cellular events leading to the subsequent reduction of metabolic
activity, actin depolymerization, trypsin insensitivity, nuclear conden-
sation and caspase-3 activation. To our knowledge, this is the ﬁrst time
adverse toxic effects evoked by RI-peptides are documented. The RI-
isomerization has become a common way of increasing the stability of
peptides, e.g. in the development of peptide vaccines and in the ﬁeld of
CPPs. Therefore, it is imperative that the adverse effects we have
observed as a consequence of this modiﬁcation become known.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamem.2010.10.019.
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